Raw Material

NovoPept Biotech Co., Ltd.: Your Professional Raw Material Manufacturer!

NovoPept is a specialized manufacturer of high-quality raw chemicals, committed to excellence in research, production, and supply of fine chemicals for a global clientele. Since our founding in 2021, we have rapidly earned a strong reputation for reliability, product quality, and customer-focused service.

First 12 3 Last 1/3

Why choose us?

Professional team

Our state-of-the-art facilities and experienced R&D team ensure the highest standards in manufacturing, quality control, and environmental compliance.

Quality assurance & testing

Every batch undergoes rigorous testing with HPLC, GC, MS, and other advanced instruments to guarantee purity, consistency, and compliance.

Sales market

Since our founding, we have been dedicated to providing innovative, reliable, and safe raw materials for global markets including USA, Europe, Canada, and Australia.

Contract manufacturing (OEM/ODM)

Flexible production solutions ranging from pilot-scale to large-scale batches, backed by advanced equipment and skilled technical teams.

Types of Raw Material

The Raw Materials Produced By Our Company Mainly Include the Following Types:

Mavacamten CAS 1642288-47-8
Mavacamten (CAS 1642288478) is a transformative, targeted therapy for obstructive HCM. With a unique MOA, established FDA approval, and strong patient interest globally, it continues to reshape cardiomyopathy treatment. Patient reported discussions emphasize lifequality improvements, monitoring logistics, and cost, giving you insight into both clinical and end user priorities that matter most.

Resmetirom CAS 920509-32-6
Resmetirom (CAS 920509-32-6), marketed as Rezdiffra, is a selective thyroid hormone receptor β (THR β) agonist approved by the FDA for the treatment of non cirrhotic NASH with moderate to advanced liver fibrosis.

Product Specifications

Mavacamten CAS 1642288-47-8

Name	Mavacamten
Synonyms/Code	MYK-461, SAR439152
CAS Number	1642288-47-8
IUPAC Name	(S)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1H,3H)-dione
Molecular Formula (MF)	C15H19N3O2
Molecular Weight (MW)	~273.34 g/mol
Mechanism of Action	Inhibits cardiac myosin, reducing the number of actin-myosin cross-bridges and decreasing the force of heart muscle contraction.
Purity	≥98%
Physical Form	White to off-white solid powder
Melting Point (MC)	198–202°C
Solubility	Soluble in DMSO and DMF
Storage (Long-Term)	Powder should be stored at −20°C

Benefits of Raw Material

Mavacamten CAS 1642288-47-8

Improved symptoms and quality of life: Patients experience significant improvements in their symptoms, such as shortness of breath, fatigue, and chest pain. This translates to a better health status and overall quality of life.
Enhanced functional capacity and exercise tolerance: Mavacamten increases exercise capacity, as measured by peak oxygen consumption (pVO2). This allows patients to perform daily activities with less difficulty.
Reduction in cardiac biomarkers: Mavacamten significantly lowers levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), which are indicators of myocardial stress and injury.
Improved long-term outcomes: Modeling studies project that mavacamten is associated with substantial net health benefits over a lifetime, including increased life-years (LYs) and quality-adjusted life-years (QALYs).

Resmetirom CAS 920509-32-6

Favorable safety & tolerability: Generally well-tolerated with mild-to-moderate GI side effects, rare serious events, and doesn't significantly disrupt overall thyroid function.
Reduces need for biopsies: Supports a shift towards non-invasive diagnostics for MASH management, improving patient access and safety.
Landmark approval: First disease-specific treatment for MASH/fibrosis, setting a new standard for liver disease therapy and inspiring further research.

Ordering Process

Set a strategy

Determine quantity, style and delivery time.

Sign contract

Provide efficient, high-quality services.

Production

Strict control and quality control at all levels.

Delivery

Delivery to customers according to contract time.

Packaging and Shipping

FAQ

Q: What condition is mavacamten used to treat?

A: Mavacamten is primarily approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. This condition is characterized by thickened heart muscle that obstructs blood flow and causes symptoms such as shortness of breath, chest pain, dizziness, and fatigue.

Q: How does mavacamten work?

A: Mavacamten works by selectively inhibiting cardiac myosin, a motor protein responsible for heart muscle contraction. By reducing excessive actin–myosin cross-bridge formation, it decreases hypercontractility and improves cardiac relaxation, thereby reducing left ventricular outflow tract obstruction.

Q: How is mavacamten different from traditional HCM treatments?

A: Unlike beta-blockers or calcium channel blockers, which indirectly reduce heart workload, mavacamten directly targets the molecular cause of hypertrophic cardiomyopathy. This disease-modifying approach can lead to structural and functional improvements in heart performance.

Q: What condition is resmetirom used to treat?

A: Resmetirom is used for the treatment of nonalcoholic steatohepatitis (NASH), also referred to as metabolic dysfunction–associated steatohepatitis (MASH), particularly in patients with liver fibrosis. This condition involves excess fat accumulation, inflammation, and progressive scarring of the liver.

Q: How does resmetirom work?

A: Resmetirom activates THR-β receptors in the liver, which regulate lipid metabolism. By stimulating these receptors, resmetirom increases fat oxidation, reduces lipid synthesis, lowers liver fat content, and improves inflammatory and fibrotic pathways associated with NASH.

Q: Why is resmetirom considered a targeted therapy?

A: Resmetirom selectively activates the beta subtype of thyroid hormone receptors, which are predominantly expressed in the liver. This selectivity helps avoid activation of THR-α receptors found in the heart and bone, reducing the risk of cardiovascular and skeletal side effects.

Q: How is resmetirom administered?

A: Resmetirom is administered orally, typically once daily. Oral dosing improves patient convenience and adherence compared to injectable therapies commonly used for metabolic disorders.

Q: What are the benefits of resmetirom for NASH patients?

A: Clinical studies have shown that resmetirom can significantly reduce liver fat, improve liver enzyme levels, and slow or reverse fibrosis progression. These effects address both the metabolic and structural components of NASH, which are critical for preventing liver failure.

As one of the leading raw material manufacturers and suppliers in China, we warmly welcome you to buy cost-efficient raw material for sale here from our factory. All chemical materials are with high quality and competitive price.